Kodiak Sciences, Inc. (KOD)
99.87
+5.61
(+5.95%)
USD |
NASDAQ |
Oct 09, 16:00
100.13
+0.26
(+0.26%)
After-Hours: 20:00
Kodiak Sciences Cash from Operations (Quarterly) : -46.24M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -46.24M |
| March 31, 2026 | -40.01M |
| December 31, 2025 | -39.38M |
| September 30, 2025 | -32.88M |
| June 30, 2025 | -34.67M |
| March 31, 2025 | -29.08M |
| December 31, 2024 | -30.07M |
| September 30, 2024 | -21.16M |
| June 30, 2024 | -26.49M |
| March 31, 2024 | -39.60M |
| December 31, 2023 | -32.24M |
| September 30, 2023 | -32.76M |
| June 30, 2023 | -41.96M |
| March 31, 2023 | -47.22M |
| December 31, 2022 | -55.08M |
| September 30, 2022 | -53.09M |
| June 30, 2022 | -55.14M |
| March 31, 2022 | -43.16M |
| Date | Value |
|---|---|
| December 31, 2021 | -59.04M |
| September 30, 2021 | -51.95M |
| June 30, 2021 | -36.66M |
| March 31, 2021 | -34.62M |
| December 31, 2020 | -27.02M |
| September 30, 2020 | -24.57M |
| June 30, 2020 | -13.90M |
| March 31, 2020 | -17.93M |
| December 31, 2019 | -11.29M |
| September 30, 2019 | -7.696M |
| June 30, 2019 | -12.95M |
| March 31, 2019 | -7.207M |
| December 31, 2018 | -8.34M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | -11.26M |
| December 31, 2017 | -4.897M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| AbbVie, Inc. | 3.436B |
| Mirum Pharmaceuticals, Inc. | -44.25M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.352M |
| Cash from Financing (Quarterly) | 2.963M |
| Free Cash Flow | -159.90M |
| Free Cash Flow Per Share (Quarterly) | -0.7439 |
| Free Cash Flow to Equity (Quarterly) | -43.35M |
| Free Cash Flow to Firm (Quarterly) | -46.59M |
| Free Cash Flow Yield | -2.76% |